PATIENT ALERT:  Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. Thank you. CLICK HERE for more details​​​​​​.

Clinical Research & Trials

USO 21507

A Phase III, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent, Inoperable or Metastatic Triple-negative Breast Cancer D926PC00001: (TROPION Breast02).

 

Disease Types: Breast Cancer Research

Available at: